Literature DB >> 6678867

The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466, PCNU), a nitrosourea with low carbamoylating activity.

B Drewinko, L Y Yang.   

Abstract

The survival response of human colorectal carcinoma cells treated in vitro for 1 h with PCNU was characterized by a threshold exponential curve, Dq = 8 micrograms/ml (1 h) and Do = 22 micrograms/ml (1 h). Continuous treatment induced decreasing degrees of cell kill although PCNU was biologically stable in solution for at least 24 h. Cells treated with PCNU were unable to recover from potentially lethal damage but were quite capable of repairing PCNU-induced sublethal damage. Thus, PCNU with different alkylating and carbamoylating than other nitrosourea congeners had similar cytotoxic and repair inhibition capacities. Any therapeutic gain in the clinical use of PCNU must derive only from its lipophilic properties and not from its superior activity at the cellular level.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6678867     DOI: 10.1007/bf00208890

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  23 in total

1.  The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents.

Authors:  R P Hill; J A Stanley
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

2.  Studies related to the mechanisms of action of cytotoxic alkylating agents: a review.

Authors:  G P WHEELER
Journal:  Cancer Res       Date:  1962-07       Impact factor: 12.701

3.  Response of exponentially growing, stationary-phase, and synchronized cultured human colon carcinoma cells to treatment with nitrosourea derivatives.

Authors:  B Drewinko; B Barlogie; E J Freireich
Journal:  Cancer Res       Date:  1979-07       Impact factor: 12.701

4.  Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas.

Authors:  G P Wheeler; B J Bowdon; J A Grimsley; H H Lloyd
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

5.  Phase I study of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466) in adults with solid tumors.

Authors:  D J Stewart; R S Benjamin; M Leavens; M Valdivieso; M A Burgess; G P Bodey
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

6.  Analysis of the growth kinetics of a human lymphoma cell line.

Authors:  B Drewinko; B Bobo; P R Roper; M A Malahy; B Barlogie; B Jansson
Journal:  Cell Tissue Kinet       Date:  1978-03

7.  Synthesis of nitrosourea derivatives of pyridine and piperidine as potential anticancer agents.

Authors:  A M Crider; R Lamey; H G Floss; J M Cassady; W J Bradner
Journal:  J Med Chem       Date:  1980-08       Impact factor: 7.446

8.  Microsomal metabolism of nitrosoureas.

Authors:  D L Hill; M C Kirk; R F Struck
Journal:  Cancer Res       Date:  1975-02       Impact factor: 12.701

9.  Cellular response to treatment with 4-(3-(2-chloroethyl)-3-nitrosoureido)-cis-cyclohexanecarboxylic acid, a water-soluble nitrosourea derivative.

Authors:  B Drewinko; C Green; T L Loo
Journal:  Cancer Treat Rep       Date:  1977-11

10.  Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man.

Authors:  R W Sponzo; V T DeVita; V T Oliverio
Journal:  Cancer       Date:  1973-05       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.